Vis enkel innførsel

dc.contributor.authorDegerud, Eiriken_US
dc.contributor.authorNygård, Ottaren_US
dc.contributor.authorDe Vogel, Stefanen_US
dc.contributor.authorHoff, Runeen_US
dc.contributor.authorSvingen, Gard Frodahl Tveitevågen_US
dc.contributor.authorPedersen, Eva Ringdalen_US
dc.contributor.authorNilsen, Dennis W.T.en_US
dc.contributor.authorNordrehaug, Jan Eriken_US
dc.contributor.authorMidttun, Øivinden_US
dc.contributor.authorUeland, Per Magneen_US
dc.contributor.authorDierkes, Juttaen_US
dc.PublishedDegerud EM, Nygård O, De Vogel S, Hoff R, Svingen GFTS, Pedersen ER, Nilsen DW, Nordrehaug JE, Midttun Ø, Ueland PM, Dierkes J. Plasma 25-hydroxyvitamin D and mortality in patients with suspected stable angina pectoris. Journal of Clinical Endocrinology and Metabolism. 2018;103(3):1161-1170eng
dc.description.abstractContext and Objective: Vitamin D status may affect cardiovascular disease (CVD) development and survival. We studied the relationship between concentrations of the circulating biomarker 25-hydroxyvitamin D (25OHD) and all-cause and cardiovascular mortality risk. Design, Setting, Participants, and Main Outcome Measures: 25OHD, the sum of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2, was analyzed in plasma samples from 4114 white patients suspected of having stable angina pectoris and was adjusted for seasonal variation. Hazard ratios (HRs) for all-cause and cardiovascular mortality were estimated by using multivariable Cox models with 25OHD as the main exposure variable, with adjustment for study site, age, sex, smoking, body mass index, estimated glomerular filtration rate, and systolic blood pressure. Results: A total of 895 (21.8%) deaths, including 407 (9.9%) from CVD causes, occurred during a mean ± standard deviation follow-up of 11.9 ± 3.0 years. Compared with the first 25OHD quartile, HRs in the second, third, and fourth quartiles were 0.64 [95% confidence interval (CI), 0.54 to 0.77], 0.56 (95% CI, 0.46 to 0.67), and 0.56 (95% CI, 0.46 to 0.67) for all-cause mortality and 0.70 (95% CI, 0.53 to 0.91), 0.60 (95% CI, 0.45 to 0.79), and 0.57 (95% CI, 0.43 to 0.75) for cardiovascular mortality, respectively. Threshold analysis demonstrated increased all-cause and CVD mortality in patients with 25OHD concentrations below ∼42.5 nmol/L. Moreover, analysis suggested increased all-cause mortality at concentrations >100 nmol/L. Conclusion: Plasma 25OHD concentrations were inversely associated with cardiovascular mortality and nonlinearly (U-shaped) associated with all-cause mortality.en_US
dc.publisherOxford University Presseng
dc.rightsAttribution CC BYeng
dc.titlePlasma 25-hydroxyvitamin D and mortality in patients with suspected stable angina pectorisen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2018 Endocrine Society
dc.source.journalJournal of Clinical Endocrinology and Metabolism

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY